Molecular Karyotyping for Amniotic Fluid Test
Cost: AED 3740.0
Symptoms, Diagnosis, and Test Details
The Molecular Karyotyping for Amniotic Fluid Test is a diagnostic test that can be performed on amniotic fluid samples to detect chromosomal abnormalities in the fetus. This test, also known as chromosomal microarray analysis (CMA), is conducted by extracting and analyzing DNA from the amniotic fluid cells. The DNA is then amplified and labeled with fluorescent dyes before being hybridized to a DNA microarray.
The DNA microarray contains thousands of small DNA fragments representing different regions of the chromosomes. The microarray is scanned, and the fluorescence intensity of each spot on the microarray is measured. By comparing the fluorescence intensity of the sample DNA to a reference DNA, any differences in DNA copy number can be detected. This technique can identify copy number variations (CNVs), which are deletions or duplications of DNA segments.
Molecular karyotyping can detect a wide range of chromosomal abnormalities, including aneuploidies (such as trisomy 21, which causes Down syndrome), microdeletions/microduplications, and other structural chromosomal abnormalities. It has a higher resolution compared to traditional karyotyping, which can only detect larger chromosomal abnormalities.
This test is typically recommended when there are indications of a potential chromosomal abnormality in the fetus, such as abnormal ultrasound findings or a family history of genetic disorders. It can also be performed if the mother is of advanced maternal age, as the risk of chromosomal abnormalities increases with age.
Test Information and Report Delivery
The Molecular Karyotyping for Amniotic Fluid Test is performed using cell culture and falls under the category of Genetics. The test is conducted by a Gynecologist in the Test Department. The sample condition required for the test is amniotic fluid.
The report for the test is usually delivered within 7-9 days. It is important to note that this test is a safe procedure, but there is a small risk of complications, such as infection or leakage of amniotic fluid.
Conclusion
Molecular Karyotyping for Amniotic Fluid Testing is a valuable diagnostic tool that can provide important information about the genetic health of the fetus. It can help parents make informed decisions about their pregnancy and prepare for any potential medical or developmental needs of the child.
| Test Name | Molecular Karyotyping for Amniotic Fluid Test |
|---|---|
| Components | |
| Price | 3740.0 AED |
| Sample Condition | |
| Report Delivery | 7-9 days |
| Method | Cell culture |
| Test type | Genetics |
| Doctor | Gynecologist |
| Test Department: | |
| Pre Test Information | |
| Test Details | Molecular karyotyping, also known as chromosomal microarray analysis (CMA), is a diagnostic test that can be performed on amniotic fluid samples. This test is used to detect chromosomal abnormalities in the fetus. During a molecular karyotyping test, DNA from the amniotic fluid cells is extracted and analyzed. The DNA is then amplified and labeled with fluorescent dyes. The labeled DNA is then hybridized to a DNA microarray, which contains thousands of small DNA fragments representing different regions of the chromosomes. The microarray is scanned, and the fluorescence intensity of each spot on the microarray is measured. By comparing the fluorescence intensity of the sample DNA to a reference DNA, any differences in DNA copy number can be detected. Copy number variations (CNVs), which are deletions or duplications of DNA segments, can be identified using this technique. Molecular karyotyping can detect a wide range of chromosomal abnormalities, including aneuploidies (such as trisomy 21, which causes Down syndrome), microdeletions/microduplications, and other structural chromosomal abnormalities. It has a higher resolution compared to traditional karyotyping, which can only detect larger chromosomal abnormalities. This test is typically recommended when there are indications of a potential chromosomal abnormality in the fetus, such as abnormal ultrasound findings or a family history of genetic disorders. It can also be performed if the mother is of advanced maternal age, as the risk of chromosomal abnormalities increases with age. Molecular karyotyping for amniotic fluid testing is a safe procedure, but there is a small risk of complications, such as infection or leakage of amniotic fluid. The test is usually performed between 15 and 20 weeks of pregnancy, and the results are typically available within two weeks. Overall, molecular karyotyping for amniotic fluid testing is a valuable diagnostic tool that can provide important information about the genetic health of the fetus. It can help parents make informed decisions about their pregnancy and prepare for any potential medical or developmental needs of the child. |
